{
    "clinical_study": {
        "@rank": "106040", 
        "arm_group": {
            "arm_group_label": "MK-5172+MK-8742", 
            "arm_group_type": "Experimental", 
            "description": "Participants receive MK-5172 100 mg + MK-8742 50 mg fixed-dose combination tablets, orally once daily for 12 weeks."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the efficacy and safety of MK-5172 100 mg in\n      combination with MK-8742 50 mg in the treatment of chronic hepatitis C virus (HCV) in\n      participants who are co-infected with human immunodeficiency virus (HIV). The primary\n      hypothesis is that the percentage of participants who receive MK-5172 + MK-8742 and achieve\n      Sustained Virologic Response after 12 weeks of therapy (SVR12) will be greater than 70%."
        }, 
        "brief_title": "An Efficacy and Safety Study of MK-5172 + MK-8742 in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus (C-EDGE COINFECTION) (MK-5172-061)", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Documented chronic HCV genotype 1 (GT1), GT4, GT5, or GT6 infection with no evidence\n             of non-typeable or mixed genotype infection\n\n          -  Treatment na\u00efve for all anti-HCV treatments\n\n          -  HIV-1 infection documented by laboratory test\n\n          -  Currently na\u00efve to treatment with any antiretroviral therapy (ART) and have no plans\n             to initiate ART during this study OR on a stable HIV ART for at least 8 weeks prior\n             to study entry\n\n          -  Not ever failed more than 1 previous HIV treatment regimen\n\n          -  Participants of reproductive potential must agree to remain abstinent from\n             heterosexual activity OR use (or have their partner use) acceptable contraception\n             during heterosexual activity while receiving study drug and for 14 days after last\n             dose of study drug.\n\n        Exclusion Criteria:\n\n          -  Evidence of decompensated liver disease manifested by the presence or history of\n             acites, esophageal or gastric variceal bleeding, hepatic encephalopathy or other\n             signs of symptoms of advanced liver disease\n\n          -  Co-infected with hepatitis B virus\n\n          -  History of malignancy <=5 years prior to study start except for adequately treated\n             basal cell or squamous cell skin cancer or in situ cervical cancer or is under\n             evaluation for other active or suspected malignancy\n\n          -  Taking or planning to take any HIV therapy that includes a ritonavir-boosted or\n             unboosted protease inhibitor, efavirenz or etravirine\n\n          -  Currently participating or has participated in a study with an investigational\n             compound within 30 days of study start and is not willing to refrain from\n             participating in another study during this study\n\n          -  Clinically-relevant drug or alcohol abuse within 12 months of study start\n\n          -  Pregnant, breast feeding, or expecting to conceive or donate eggs from at least 2\n             weeks prior to study start throughout treatment and follow up, or longer if dictated\n             by local regulations\n\n          -  Organ transplants (including hematopoietic stem cell transplants) other than cornea\n             and hair\n\n          -  Poor venous access\n\n          -  History of gastric surgery (e.g., stapling, bypass) or history of malabsorption\n             disorders (e.g., celiac sprue disease)\n\n          -  Medical condition requiring, or likely to require, chronic systemic adminstration of\n             corticosteroids during this study\n\n          -  History of opportunistic infection in the 6 months prior to study start\n\n          -  Use of HIV drugs other than a dual nucleoside reverse transcriptase inhibitor (NRTI)\n             backbone of tenofovir or abacavir and either emtricitibine or lamivudine PLUS\n             raltegravir (or dolutegravir or rilpivirine)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02105662", 
            "org_study_id": "5172-061", 
            "secondary_id": "2014-000342-30"
        }, 
        "intervention": {
            "arm_group_label": "MK-5172+MK-8742", 
            "intervention_name": "MK-5172 100 mg/MK-8742 50 mg fixed-dose combination tablets", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 2, 2014", 
        "number_of_arms": "1", 
        "official_title": "A Phase III Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Na\u00efve Subjects With Chronic HCV GT1, GT4, GT5, and GT6 Infection Who Are Co-Infected With HIV", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Percentage of participants achieving Sustained Virologic Response 12 weeks after the end of all study therapy (SVR12)", 
                "safety_issue": "No", 
                "time_frame": "Follow-up Week 12 (Up to 24 weeks)"
            }, 
            {
                "measure": "Percentage of participants experiencing adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 weeks"
            }, 
            {
                "measure": "Percentage of participants discontinuing study drug due to adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 12 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02105662"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Percentage of participants achieving Sustained Virologic Response 24 weeks after the end of all study therapy (SVR24)", 
            "safety_issue": "No", 
            "time_frame": "Follow-up Week 24 (Up to 36 weeks)"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}